Drugs / TEREVALEFIM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04958187 | Jul → Oct 2021 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 1 | NCT04898907 | Jun → Sep 2021 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 1 | NCT04931524 | May → Jun 2021 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04459676 Comparator | Jul 2020 → Apr 2021 | COVID-19, pneumonia | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 2 | NCT02771509 Comparator | Feb 2017 → Aug 2021 | acute kidney injury | Angion Biomedica Corp | Unknown | No outcome recorded |
| Phase 3 | NCT02474667 Comparator | Mar 2016 → Sep 2021 | — | Angion Biomedica Corp | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-12-10 | CSL Behring | Results Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury csl.com ↗ |
| 2021-10-27 | CSL Behring | Results Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function csl.com ↗
ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing DGF. |
All press releases naming this drug 4 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEREVALEFIM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650326 ↗ |
| Known as | ANG-3777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02474667 ↗ |
| Known as | BB3 | “ANG-3777 (Formerly BB3) to Improve Graft Function” NCT02474667 ↗ |
| Known as | carbon-14-[14C]-ANG-3777 | “Drug: carbon-14-[14C]-ANG-3777” NCT04931524 ↗ |
| Known as | Refanalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650326 ↗ |
| Known as | SNV-003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650326 ↗ |
| Action | Activate | “Hepatocyte growth factor receptor agonist” CHEMBL4650326 ↗ |
| Modality | Small molecule | — CHEMBL4650326 ↗ |
| Route | Intravenous | “Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row” NCT02474667 ↗ |
| Target | MET | “Hepatocyte growth factor receptor agonist” CHEMBL4650326 ↗ |